Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-Dose Decitabine in MDS Post Azacytidine Failure
NCT00113321Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2005
- Primary completion
- Nov 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of decitabine in myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Overall Response. Started Mar 2005; status: terminated.
02
Drugs
decitabine
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT00113321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00113321.